Comparative analysis reveals NK nanovesicles improve drug delivery and cytotoxicity in cancer therapy, indicating a new avenue in tumor immunotherapy.
Purpose: Natural killer (NK) cell-derived extracellular vesicles (NK-EVs) have garnered significant research interest in the field of tumor immunotherapy. However, the large-scale production of NK-EVs remains a major challenge, limiting their clinical application. This study aims to develop a simple and efficient method for the preparation of NK cell-derived nanovesicles (NK-NVs) and to evaluate their cytotoxicity and drug delivery potential. Methods: In this study, we efficiently produced large quantities of NK-NVs by extruding NK cells. We conducted comprehensive characterization and protein profiling analyses of NK cells, NK-EVs, and NK-NVs. The cytotoxicity and cellular uptake of NK-NVs were evaluated, and the internalization mechanism was explored. To assess the drug delivery capability, doxorubicin (DOX) was loaded into NK-NVs (NK-NVs-DOX) using various loading strategies, including co-incubation, sonication, extrusion, and electroporation. We thoroughly evaluated the drug loading efficiency, particle size, stability, and cytotoxicity of NK-NVs-DOX. Results: Extrusion-derived NK-NVs exhibited a remarkable 402.18-fold increase in particle yield and a 325.76-fold enhancement in protein yield compared to ultracentrifugation-isolated NK-EVs, while maintaining comparable morphology and EV-specific markers (Alix, TSG101, CD9). Functionally, NK-NVs induced delayed cytotoxicity against cancer cells via caveolin-mediated endocytosis, selectively sparing normal cells. Proteomic analysis revealed that NK-NVs shared 7,366 proteins with NK cells, surpassing the 5,326 proteins found in NK-EVs. Furthermore, extrusion-optimized NK-NVs-DOX demonstrated pH-sensitive drug release (30% higher at pH 5.5), significantly enhanced anti-cancer effects across four cancer cell lines, and stable drug retention for up to 28 days at 4°C, highlighting their promising therapeutic potential. Conclusion: Extrusion-derived NK-NVs offer a low-cost, rapid, and high-yield production method while selectively inducing cytotoxicity in cancer cells. Their pH-sensitive drug release enhances drug loading stability. These advantages establish NK-NVs as a promising and scalable platform for tumor immunotherapy and drug delivery with significant clinical potential.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: